Sun Pharma’s New Jersey manufacturing overhaul puts 96 jobs at risk

pharmafile | November 26, 2018 | News story | Manufacturing and Production, Sales and Marketing Sun Pharma, manufacturing, pharma 

Indian pharma firm Sun Pharma has announced it is to combine its New Jersey manufacturing operations in a bid to “improve cost efficiencies, it has emerged – a move which puts almost 100 jobs at risk.

Specifically, the company plans to relocate operations at its facility in Cranbury to its site in New Brunswick, which will threaten 96 positions. The firm’s intention was confirmed in a WARN notice published by the New Jersey Department of Labor and Workforce Development

“Sun Pharma is consolidating its manufacturing operations at New Brunswick and Cranbury into one location, New Brunswick,” a company spokesperson said. “The restructuring is aimed at optimising our manufacturing operations and improving cost efficiencies in the increasingly competitive US market.”

The company confirmed that the affected employees will receive a severance package and will able to relocate.

“We are offering full support to the employees at Cranbury and helping them with internal reallocations and outplacement services.”

Matt Fellows

Related Content

Astellas plans to invest over €330m in new facility in Ireland

Astellas Pharma has announced that it is preparing to submit a planning application to build …

Sun Pharma and Pharmazz enter license agreement for Tyvalzi in India

Sun Pharma has announced that one of its wholly owned subsidiaries has entered into a …

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Latest content